Skip to main content
Premium Trial:

Request an Annual Quote

BioTek, Gyrasol Ink Co-marketing Pact

NEW YORK (GenomeWeb News) – BioTek Instruments has struck a co-marketing agreement with the specialty assay developer Gyrasol, under which the companies will jointly promote an assay platform with a microplate reader, BioTek said today.
 
Under the agreement, the companies will promote the Gyrasol Sensor, a fluorescence-based assay platform, on BioTek’s Synergy 4 Hybrid microplate reader.
 
The Gyrasol Sensor is used in screening for kinases and phosphatases in a homogeneous format, and the BioTek microplate reader combines filter-based and monochromator-based fluorescence detection in one unit, BioTek said. The Synergy microplate reader offers multi-detection for “an unlimited number of current and future microplate-based assays,” the company said.
 
Further terms of the alliance were not disclosed.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.